CAMP4 Therapeutics Secures Rare Pediatric Disease Designation for CMP-CPS-001 for the Treatment of Urea Cycle Disorders
August 27, 2024 08:00 ET
|
CAMP4 Therapeutics Corp.
CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics, a clinical-stage biotechnology company developing a pipeline of RNA-based therapeutics designed to upregulate gene expression...